Logo

SYRS

Syros Pharmaceuticals, Inc.

SYRS

Syros Pharmaceuticals, Inc. • NASDAQ
$0.00 ▼ -37.50% (-0.00)
Market Cap $13415
52w High $0.31
52w Low $0.00
Dividend Yield 0%
P/E 0
Volume 904
Outstanding Shares 26.83M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2024 $0 $26.182M ▼ $-6.396M ▲ 0% $-0.16 ▲ $-4.759M ▲
Q2-2024 $0 $27.416M ▼ $-23.327M ▼ 0% $-0.59 ▼ $-21.614M ▼
Q1-2024 $0 ▼ $30.587M ▲ $-3.708M ▲ 0% ▲ $-0.095 ▲ $-2.067M ▲
Q4-2023 $386K ▼ $27.112M ▼ $-64.384M ▼ -16.68K% ▼ $-2.18 ▼ $-62.776M ▼
Q3-2023 $3.762M $38.398M $-40.143M -1.067K% $-1.43 $-38.224M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2024 $58.275M ▼ $84.995M ▼ $96.118M ▼ $-11.123M ▼
Q2-2024 $78.964M ▼ $106.722M ▼ $113.074M ▼ $-6.352M ▼
Q1-2024 $108.304M ▼ $134.728M ▼ $119.671M ▼ $15.057M ▼
Q4-2023 $139.526M ▲ $168.174M ▲ $151.512M ▲ $16.662M ▼
Q3-2023 $112.219M $147.795M $111.493M $36.302M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2024 $-6.396M ▲ $-20.689M ▲ $0 ▼ $0 ▼ $-20.689M ▼ $-20.689M ▲
Q2-2024 $-23.327M ▼ $-29.667M ▲ $25.067M ▲ $41K ▲ $-4.559M ▲ $-29.667M ▲
Q1-2024 $-3.708M ▲ $-31.098M ▼ $-24.64M ▼ $-265K ▼ $-56.003M ▼ $-31.098M ▼
Q4-2023 $-64.384M ▼ $-18.565M ▲ $1.522M ▼ $43.38M ▲ $27.307M ▲ $-18.603M ▲
Q3-2023 $-40.143M $-31.858M $28.64M $-5K $-3.223M $-31.858M

Five-Year Company Overview

Income Statement

Income Statement Syros is still essentially a pre‑revenue biotech company. Reported revenue has been minimal for several years and does not yet reflect a commercial product. At the same time, operating and net losses are sizable and persistent, driven by research, clinical trials, and overhead. Losses widened somewhat in the most recent year versus the prior one, indicating that spending remains high relative to the tiny revenue base. Per‑share figures are noisy because of capital structure changes (like the reverse split), but the underlying story is clear: the business is still in the investment phase and far from profitability.

Balance Sheet

Balance Sheet The balance sheet is dominated by cash and similar liquid resources, which is typical for a clinical‑stage biotech with no products on the market. However, total assets and cash have both trended down, reflecting ongoing use of funds to cover operating losses. Debt has stayed roughly similar in absolute terms, but shareholder equity has shrunk, which means the company’s cushion against losses has become thinner and leverage looks higher relative to its equity base. Overall, the balance sheet underscores dependence on fresh financing over time to support operations and clinical programs.

Cash Flow

Cash Flow Syros has been consistently burning cash from operations, with negative operating and free cash flow each year shown. The pattern suggests a steady outflow to fund R&D and clinical trials, with only modest variation from year to year rather than a move toward cash breakeven. Capital spending on physical assets is very low, so nearly all cash use is tied to people, trials, and the pipeline rather than buildings or equipment. This profile is typical for a development‑stage biotech, but it also means the company will likely need periodic external capital to maintain its programs unless a partner or commercial product meaningfully changes the cash picture.

Competitive Edge

Competitive Edge Syros operates in a very competitive oncology and hematology landscape, but it has carved out a differentiated niche around controlling gene expression and targeting specific patient subgroups. Its gene control platform and focus on regulatory DNA regions give it a specialized scientific angle that is not easy to copy quickly. Exclusive rights to key drugs and biomarkers, plus a growing intellectual property portfolio, add to this. On the other hand, Syros is small compared with major pharma and biotech players, has no approved products yet, and faces clinical and regulatory uncertainty. The halted enrollment in one AML trial highlights execution and data‑risk that competitors also face. Its competitive position is therefore promising scientifically but still unproven commercially.

Innovation and R&D

Innovation and R&D Innovation is the core of Syros’ story. The company is pushing a novel gene control platform aimed at diseases driven by misregulated gene expression, especially in blood cancers. Its lead program, tamibarotene, is a targeted therapy for patients identified by a proprietary biomarker, which supports a personalized‑medicine strategy and could be a meaningful differentiator if late‑stage data are strong. Additional assets, such as the oral arsenic candidate for leukemia and a selective CDK7 inhibitor for solid tumors, broaden the pipeline but are earlier and have already seen some reprioritization and delays. Overall, Syros is clearly R&D‑heavy, with a concentrated bet on a few main programs, creating both upside if trials succeed and elevated risk if key readouts disappoint.

Summary

Syros is a classic clinical‑stage biotech: scientifically ambitious, financially loss‑making, and highly dependent on future trial outcomes and financing. The financial statements show almost no revenue, recurring losses, and steady cash burn, with a shrinking equity base and a balance sheet that leans heavily on cash reserves. From a strategic standpoint, the company’s gene control platform, biomarker‑driven approach, and focused hematology pipeline offer real differentiation but remain commercially untested. The upcoming pivotal data for tamibarotene and the future of its other lead candidates will be decisive in determining whether today’s heavy investment and financial risk translate into durable value in the longer term.